Recent studies have demonstrated pleiotropic effects of statins in various mouse models of kidney disease. In this study, Townes humanized sickle cell mice were treated for 8 weeks with atorvastatin at a dose of 10 mg/kg/ day starting at 10 weeks of age. Treatment with atorvastatin significantly reduced albuminuria, and improved both urine concentrating ability and glomerular filtration rate. Atorvastatin also decreased markers of kidney injury and endothelial activation, and ameliorated oxidant stress in renal tissues and peripheral macrophages. Atorvastatin downregulated the expression of mRNA levels of the NADPH oxidases, Cybb (also termed Nox2) and Nox4, which are major sources of oxidant stress in the kidney. These findings highlight the pleiotropic effects of atorvastatin and suggest that it may provide beneficial effects in sickle cell nephropathy.
Sickle cell disease (SCD) affects approximately 100 000 people in the United States. It is an autosomal recessive disorder due to a single point mutation in the HBB (b-globin) gene of, with haemoglobin polymerization leading to characteristic red blood cell (RBC) sickling, vaso-occlusion and haemolysis. Beginning in infancy, individuals with SCD experience a broad range of acute and chronic complications due to vascular occlusion and endothelial damage by sickled RBCs and other cellular elements, resulting in end organ damage, including renal dysfunction (Ataga et al, 2014) .
Sickle cell nephropathy (SCN) is the term used to describe the constellation of renal complications that results from SCD. Renal dysfunction begins early in the first decade of life and is commonly manifested as microalbuminuria; occurring in approximately 20% of SCD patients aged 18 years and under (McPherson Yee et al, 2011) . The problem worsens with age and approximately 68% patients over the age of 40 years have evidence of SCN, proteinuria and decreased renal function (Guasch et al, 2006) . End stage renal disease (ESRD) develops in 4Á2-11Á6% of adults with SCD and is an independent predictor of premature mortality in young adults (Powars et al, 1991 (Powars et al, , 2005 . Furthermore, ESRD is associated with an increased risk of mortality compared with those without this diagnosis (Abbott et al, 2002) .
The pathophysiology of SCN is not well-understood and commonly attributed to repeated vaso-occlusive crises (VOCs), intermittent hypoxia and impaired protective cellular mechanisms. Repeated episodes of hypoxia/reperfusion lead to endothelial activation, reduced nitric oxide bioavailability and augmented oxidative stress. Endothelial activation, defined by endothelial expression of cell-surface adhesion molecules, such as soluble vascular cell adhesion molecule-1 (sVCAM-1), perpetuates inflammation, resulting in vascular disease. SCD creates a state of increased oxidative stress, with increased production of reactive oxygen species (ROS), the effects of which contribute significantly to the long-term pathology of SCD (Kupesiz et al, 2012) . NADPH oxidase (NOX), a membrane-bound enzymatic complex, is the most important source of ROS in the vasculature, and produces superoxide when activated (Margaritis et al, 2014) . NOX activity has been implicated in SCD-induced endothelial dysfunction in sickle cell mice (Wood et al, 2005) .
Current treatment options for SCN aim to decrease albuminuria by initiating an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) (Falk et al, 1992; Foucan et al, 1998) . Hydroxycarbamide (also termed Hydroxyurea), a drug that increases fetal haemoglobin and reduces erythrocyte sickling, decreases albuminuria in patients with SCD (Fitzhugh et al, 2005; Bartolucci et al, 2016; Tehseen et al, 2017) . However, available drug treatment options for albuminuria in patients with SCD remain limited, with no large, adequately controlled studies demonstrating the efficacy of any interventions (Quinn et al, 2017) . Statins (3-hydroxy-3-methylgutaryl (HMG)-CoA reductase inhibitors) exert lipidindependent effects, including improvement of endothelial function, upregulation of nitric oxide (NO) and reduction in markers of oxidative stress (Margaritis et al, 2014) . Nitric oxide donors have been shown to suppress the expression of endothelial adhesion molecules. Statins may restore endothelial function that is altered during repeated episodes of hypoxia-reperfusion associated with VOCs and inhibit vascular inflammation and oxidation (Zhou et al, 2004 (Zhou et al, , 2008 Zhou & Liao, 2010) . Statins have been used in various animal models of proteinuric kidney disease, in diabetic nephropathy and anti-glomerular basement membrane disease, demonstrating a decrease in albuminuria and associated pathological changes (Fujii et al, 2007; Eller et al, 2010; Zoja et al, 2010) .
We hypothesized that atorvastatin would downregulate mediators of inflammation and oxidant stress, which aid in restoring cytoprotective balance, and slow the progression of SCN. Here we studied the effects of atorvastatin therapy on renal function and markers of oxidative stress in a murine model of SCD.
Materials and methods

Animals
All mice were maintained and studied in accordance with the US National Research Council's Guide for the Care and use of Laboratory Animals. The protocol was approved by the Institutional Animal Care and Use Committee of Emory University. Male and female homozygous humanized sickle cell mice aged of 8-10 weeks, expressing human beta-sickle globin (SS) were used (Ryan et al, 1997; Wu et al, 2006) . Similar age-matched male and female Townes mice expressing normal human haemoglobin (AA) were controls. There were three experimental groups with 8 mice per group: AA and SS mice, which were treated with vehicle (controls), and SS mice treated with atorvastatin. Mice were housed under conditions of constant temperature and humidity and exposed to a 12-h light/dark cycle. All mice were given free access to food and water. Twenty-four hour urine samples were collected at two time points, baseline (prior to initiation of treatment) and at 8 weeks.
Mice were placed in standard metabolic cages and allowed to adapt for 24 h prior to obtaining a 24 h urine sample to measure urine albumin, creatinine, nephrin and kidney injury molecule-1 (KIM-1). Mice were water deprived for 12 h and first morning urine was obtained to measure maximal urine concentrating ability using a vapour pressure osmometer (VAPRO, Elitech Company, Logan, UT, USA). Urine osmolality was measured prior to the initiation of treatment and after 4 and 8 weeks of treatment.
Drug treatments
Atorvastatin was obtained from Pfizer Inc. (New York, NY, USA), through its drug assistance programme and reconstituted in 0Á5% methylcellulose, as recommended. SS mice were orally gavaged daily with atorvastatin for 8 weeks. Atorvastatin was administered at 10 mg/kg/day, a dose that has previously been shown to decrease albuminuria, lower cholesterol and decrease inflammation (Eller et al, 2010; Gotoh et al, 2013; Pan et al, 2016) . Mice treated with the vehicle (0Á5% methylcellulose) served as controls. Control mice were orally gavaged daily for 8 weeks.
Urine analysis
Creatinine. Urine creatinine was measured using the Beckman Creatinine analyser (Beckman, Brea, CA, USA), which determined urine creatinine by the Jaffe rate method as previously published (Cottrell & Frings, 1979) .
Albumin. Urine albumin was measured using the Albumin Mouse enzyme-linked immunosorbent assay (ELISA) kit (ab108792; Abcam, Cambridge, MA, USA). Urine was diluted 1:400, as per manufacturer recommendations. All samples and standards were run in duplicate. Unknown sample concentration was determined from a standard curve. Urine albumin was expressed as albumin/creatinine ratio and normalized to 24-h urine volume [albumin (lg/ml) 9 24-h collected volume (ml)].
Urine biomarkers. The concentration of urine KIM-1, nephrin and neutrophil gelatinase-associated lipocalin (NGAL) was measured using the KIM-1 mouse ELISA kit (ab119596; Abcam), Cloud-Clone Corp (Katy, TX, USA) nephrin mouse ELISA kit (SEA937Mu) and BIOPORTO Diagnostics (Hellerup, Denmark) mouse NGAL ELISA Kit (KIT 042), respectively. All ELISA kits were processed following manufacturers directions. Unknown sample concentrations were determined from standard curves. Urine biomarkers were expressed as a ratio of urine creatinine (see Appendix SI).
Plasma biomarkers. The concentration of plasma sVCAM-1 was measured using a mouse ELISA Kit (MCV00; R&D Systems, Minneapolis, MN, USA) (see Appendix SI).
Procedures
Blood was collected via retro-orbital bleeding into sodium EDTA tubes under isoflurane anesthesia at two time points. The first-time point occurred at initiation of the experiment (prior to receipt of study treatment) and the second-time point occurred at 8 weeks. Complete blood counts (CBC) were measured using a HemaTrue machine (HESKA Corp., Loveland, CO, USA) at the beginning of the experiment and after 8 weeks of treatment.
GFR
Glomerular filtration rate (GFR) was estimated at three time points, 0, 4 and 8 weeks. GFR was calculated using plasma clearance of 5% fluorescein isothiocyanate (FITC)-Inulin following a single bolus of intravenous injection as previously described (Qi, 2003) . Approximately 2 ll of blood was collected at 3, 7, 10,15, 35, 55, 75 and 95 min post-injection of FITC-inulin for determination of FITC concentration by fluorescence.
Renal histology
The excised kidneys were fixed in formalin and processed by the Pathology Core at the Children's Healthcare of Atlanta. 3-lm sections of kidney samples were stained with Masson trichrome, haematoxylin and eosin, and periodic-acid-Schiff stain. The same pathologist analysed all renal biopsies and was blinded to the treatment groups. The presence of glomerular changes, including basement membrane thickening, focal segmental sclerosis, mesangial hypercellularity, mesangial expansion, interstitial inflammation, interstitial fibrosis and tubular atrophy, were evaluated according to the Nephrotic Syndrome Study Network (NEPTUNE) digital pathology scoring system (Barisoni et al, 2016) . AA mice served as controls. Mesangial hypercellularity was defined as greater than 3 mesangial cells: 0 -none (≤3 mesangial cells), 1-mild (3-4 mesangial cells), 2-moderate (5-6 mesangial cells), and 3-severe (>6 mesangial cells).
Estimation of glomerular area
Glomerular area was estimated by tracing glomerular tufts using the NanoZoomer Digital Pathology computer program, 2015) (Hamamatsu Photonics K.K., Hamamatsu, Japan). Approximately 50 glomeruli were measured per mouse.
Flow analysis
We collected blood as described above for red blood cell (RBC), white blood cell (WBC) and reticulocyte analysis. For RBC and reticulocyte analysis, blood was incubated with TER-119, CD45 and Thiazole at room temperature for 15 min (Table SI) . The remaining blood was processed utilizing dextran sedimentation and hypotonic lysis (Appendix SI). For WBC analysis, antibodies CD45, CD19, Ly6G, CD3, Live/Dead, and CD11b (Table SI) and GAPDH served as the internal control (Schmittgen & Livak, 2008) .
GSH, GSSG, CYS and CYSS levels in mouse kidney
Kidney tissue was used to measure reduced glutathione (GSH), glutathione disulfide (GSSG), reduced cysteine (CYS) and cystine (CYSS) as previously reported (Yeligar et al, 2014) . The redox potential (E h ) of the thiol pair was calculated using the Nernst equation as previously reported. (Yeligar et al, 2014 ) A more positive E h indicates greater oxidation of the thiol pair.
Statistical analysis
A sample size of eight mice per group would be needed to achieve a power of 0Á8, at an alpha of 0Á05 with a 95% confidence interval. Data are presented as mean AE standard error of the mean (SEM). Comparisons between groups were made by paired t-tests, with P < 0Á05 being considered statistically significant. Welch's correction was applied if F-test demonstrated significance. Mann-Whitney test was employed in datasets that did not demonstrate normal distribution, with P < 0Á05 considered significant. Two-factor repeated measures analysis of variance models with one within-factor (time: 0, 4, 8 weeks) and one between-factor (group: SS vehicle versus SS statin) were employed. Models included a treatment-by-time interaction and adjusted least square mean estimates with reporting of standard errors. To determine which time points were significantly different, post-hoc pairwise comparisons between groups and across groups were performed. Unadjusted P-values were reported. Data analysis was carried out using Prism v6 (Graphpad Software Inc, La Jolla, CA, USA). (Fig 1A) . Daily treatment of SS mice with atorvastatin significantly increased GFR, which was first observed after 4 weeks of treatment and was maintained after 8 weeks of treatment, (SS statin 4 weeks: 115Á4 AE 3Á2 ll/min and 8 weeks: 118Á7 AE 1Á8 ll/min vs. SS vehicle 4 weeks: 101Á0 AE 2Á0 ll/min (P < 0Á01) and 8 weeks: 103Á6 AE 1Á9 ll/min, P < 0Á001) (Fig 1B) .
Treatment with atorvastatin over 8 weeks resulted in significant improvement in the albumin excretion rate, (AA: 228Á9 AE 65Á6 lg/day, SS vehicle: 321Á5 AE 81Á1 lg/day vs. SS statin 219Á1 AE 60Á9 lg/day) (Fig 2A) . The albumin to creatinine ratio demonstrated a significant decrease in atorvastatin treated mice, P < 0Á05 (Fig 2B) . SS mice have higher urine volume compared to AA mice (P < 0Á01), probably due to their poor urine concentrating abilities despite water deprivation, which will achieve maximum concentrating ability (Fig 2C) . After 8 weeks of treatment, atorvastatin significantly improved urine volume in SS treated mice (P < 0Á05). No significant changes were observed in haematological indices, haematocrit, RBC count or reticulocyte count.
Renal histology
To determine changes in renal histology due to atorvastatin treatment, glomerular tuft size was assessed in the treatment groups. Non-sickle phenotype, AA mice demonstrate significantly smaller mean glomerular area (2595 AE 82Á6 lm 2 ) compared to SS mice (3712 AE 76Á0 lm 2 ), P < 0Á001 (Fig 3A) . Treatment with atorvastatin significantly improved mean glomerular tuft area (3387 AE 76Á36 lm 2 ), P < 0Á01. Figure 3B , demonstrates left curve shift to smaller glomerular area in atorvastatin-treated mice. Mesangial hypercellularity and mesangial matrix expansion was identified in SS mice. There were no glomerular basement membrane changes or focal segmental sclerosis identified. Glomeruli that were most affected in the sections were used to assess for mesangial matrix expansion and mesangial hypercellularity. However, there were no qualitative differences found between the two treated SS mice groups. 
Biomarkers of renal injury in sickle cell nephropathy
We evaluated biomarkers of renal glomerular and tubular injury to assess the ability to predict early renal disease. We studied urinary KIM-1, nephrin and NGAL. Both urinary nephrin and KIM-1 were significantly lower in AA mice. After 8 weeks of treatment with atorvastatin, urine KIM-1 significantly improved in SS mice (P < 0Á05) (Fig 4) . No significant decreases were observed in the levels of urine NGAL and nephrin following 8 weeks of treatment. However, there was a trend towards a significant decrease in urine nephrin in atorvastatin-treated SS mice (SS vehicle 6Á75 AE 1Á2 ng/day vs. SS statin 4Á0 AE 0Á5 ng/day, P = 0Á056). In order to assess the effect of atorvastatin on endothelial activation, we analysed plasma levels of sVCAM-1, an adhesion molecule that is upregulated during endothelial activation. AA mice had significantly lower levels of sVCAM-1 compared with SS mice (Fig 4D) . After treatment with atorvastatin, there was a significant decrease in the plasma level of sVCAM-1 compared with vehicle-treated SS mice (1256 AE 55Á4 ng/ml vs. 1403 AE 21Á4 ng/ml, P < 0Á05). Atorvastatin treatment improves renal function in Sickle Cell mice. Sickle cell mice were treated with 10 mg/kg/day Atorvastatin for 8 weeks. Significant improvement in maximal urinary concentrating ability (water-deprived) and glomerular filtration rate (GFR) was demonstrated at 4 and 8 weeks (A) and (B), n = 8. **P < 0Á01 and ***P < 0Á001.
Fig 2.
Biomarkers of renal function and haematological indices. Sickle cell mice treated with Atorvastatin for 8 weeks demonstrated significant decrease in urine albumin excretion rate (A), albumin to creatinine ratio (B) and urine volume (24 h collection) (C) P < 0Á05, n = 8. Haematological markers of sickle cell disease did not change with Atorvastatin treatment (C, D and E), n = 8. Cr, creatinine; Hb, haemoglobin concentration; RBC, red blood cell count; Retics, reticulocytes; U-Alb, urine albuin.
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Renal oxidative stress
To further understand the role of oxidant stress in SCD, we employed flow cytometry studies for measurement of cellular ROS. Our analyses confirmed a significant burden of oxidant stress in RBC, WBC and neutrophils of SS mice compared to AA mice (Fig 5A) . Specifically, after 8 weeks of treatment with atorvastatin, oxidant stress was significantly decreased in macrophages, P < 0Á05 (Fig 5B) . We did not find significant changes in oxidant stress in either RBC, CD19 cells, Urinary and Plasma Biomarkers in sickle cell neuropathy. After 8 weeks of Atorvastatin treatment, sickle cell mice demonstrated significant decrease in KIM-1, *P < 0Á05 (A) without seeing significant changes in urine (Ur) Nephrin and NGAL (B and C). SS mice have elevated levels of Ur KIM-1 and Ur Nephrin (A and B), *P < 0Á05. C. Plasma (Pla) sVCAM1 is elevated in SS mice, ***P < 0Á001. After 8 weeks of statin treatment there is a significant decrease in plasma sVCAM1, **P < 0Á01.
CD3 cells or neutrophils. However, neutrophils and B cells showed a trend towards a decrease in oxidant stress, P = 0Á052 and P = 0Á069 respectively.
We used high performance liquid chromatography to measure thiol/disulfide redox couples GSH/GSSG, CYS/CYSS levels in SS mice kidney tissue. There was no significant difference in the redox potential of GSH/GSSG with atorvastatin treatment. A reductive shift in CYS/CYSS pair was demonstrated following treatment with atorvastatin, indicating significant decrease in oxidant stress (Fig 5C) .
mRNA expression of Cybb, Nox4 and Edn1 in renal tissue
To further determine the level of oxidative stress in the kidney of SS mice we measured mRNA levels of Cybb, Nox4 and Edn1. SS mice had significantly higher levels of Cybb, Nox4 and Edn1 mRNA in whole kidney than treated SS mice (Fig 6) .
Discussion
We demonstrate that atorvastatin improves both GFR and urine concentrating ability and reduces albuminuria in mice with SCN. Although the effects of statins on the progression of kidney disease in human clinical trials remain controversial, studies have demonstrated significant improvement in proteinuria or albuminuria following treatment with statins as summarized in a recent meta-analysis (Su et al, 2016) . A small pilot study examining the effect of simvastatin in SCD patients found significant decreases in markers of inflammation and reduction in the frequency of pain episodes (Hoppe Baseline increase in oxidant stress is significant in SS mice in RBC, WBC and neutrophils, *P <0Á05 and **P < 0Á01. (B) Significant decrease in oxidant stress in macrophages of Atorvastatin treated SS mice, *P < 0Á05. (C) Redox potential of thiol pairs were calculated in renal tissue of SS vehicle and SS statin treated mice by high performance liquid chromatography. Results were normalized to kidney weight for each sample, *P < 0Á05. CYS, cysteine; CYSS, cystine; GSH, glutathione; GSSG, glutathione disulfide; MFI, mean fluorescence intensity; RBC, red blood cell; WBC, white blood cell. 2017) . In this study, treatment with simvastatin for 3 months resulted in decreased plasma levels of the endothelial marker soluble E-selectin but not sVCAM-1. However, the effects of statins in patients with SCN have not been studied.
Atorvastatin in Sickle Cell
The humanized knock-in sickle cell mice utilized in this study provides an excellent model of SCD that recapitulates all the major features of sickle cell pathology in humans (Wu et al, 2006; Hyacinth et al, 2017; Sun et al, 2017) . The experimental and control groups of mice studied in this experiment were similar at baseline. They demonstrated SCN with urine concentrating defect, proteinuria or albuminuria and decreased renal function at 10 weeks of age whereas the nonsickle mice had normal renal function. As such, our model adequately represents renal disease found in SCN. We demonstrate improvement in albuminuria after 4 weeks of daily treatment, which was maintained at 8 weeks. While our findings are limited to 8 weeks, we may have observed further improvement with more prolonged treatment. As albuminuria is a sensitive marker of glomerular damage, which precedes development of overt renal insufficiency, in patients with SCD (Guasch et al, 2006) , treatment beginning prior to 10 weeks in our mice may also prevent the development of albuminuria.
In this study, GFR was assessed using FITC-inulin clearance in mice at 8-10 weeks of age. Glomerular hyperfiltration is seen early in children with SCD, with return to normal GFR values in the second decade of life (Wigfall, 2000) . While children usually present with hyperfiltration, we studied adult mice and believe that, at this age, renal dysfunction is already advanced and hyperfiltration would be seen at a younger age. It is tempting to posit that the improvement in renal function observed in these mice may also halt progression of disease.
Glomerular hypertrophy is an early sign of SCN and has been seen in children as young as 2 years of age (Sharpe & Thein, 2011) . Our histological examination demonstrated glomerular hypertrophy in SS mice in comparison to AA mice. We did not find other significant pathological differences, interstitial fibrosis or focal segmental sclerosis, between SS and AA mice. However, we found that treatment with atorvastatin significantly improved glomerular tuft size.
We also found that urine concentrating ability greatly improved following treatment with atorvastatin. Hyposthenuria occurs early in life in SCD patients and is one of the first manifestations of SCN in children. Chronic RBC transfusions were reported to improve urine osmolality (Statius van Eps et al, 1970) and albuminuria (Alvarez et al, 2017) , however this modality carries the risk of multiple complications, including allo-immunization and iron overload.
Albuminuria is a reliable marker of glomerular disease, but novel markers are needed to predict early disease prior to development of albuminuria. Urine and serum biomarkers of renal injury have been studied to assess their ability to predict early disease. Recent studies demonstrated correlation between presence of albuminuria and elevated urine KIM-1 in SCD patients (Hamideh et al, 2014) . In our study, we evaluated biomarkers of tubular and glomerular injury, KIM-1, nephrin and NGAL, in SS mice. KIM-1 is a trans-membrane protein that is not expressed in normal kidney but becomes expressed upon significant proximal tubular injury (Koyner et al, 2010) . Nephrin is expressed in the glomerular podocytes of the kidneys and plays an important role in maintaining the barrier in the glomerular capillary. Chang et al (2012) found nephrin to be a sensitive marker of glomerular injury and that it was detected before albuminuria developed in animal models. NGAL is expressed and secreted by renal tubular cells, collecting duct and has been shown to correlate with measured GFR and may be a potential marker for chronic kidney disease (Vanmassenhove et al, 2013) . We found that KIM-1 level correlated with albuminuria and showed significant improvement following treatment with atorvastatin. In contrast, no significant improvements in urine NGAL or nephrin were observed, although there was a trend to improvement with urine Expression of Cybb, Nox4 and Edn1 significantly decreased after 8 weeks of Atorvastatin treatment (A, B and C), **P < 0Á01 and ***P < 0Á001, n = 6. mRNA expression of Cybb, Nox4 and Edn1 was normalized to SS mice and Gapdh served as internal control.
nephrin following treatment with atorvastatin. However, a longer dosing period or increased number of mice may need to be treated with atorvastatin to demonstrate significance. In recent study, Sundaram et al (2011) observed subnormal urine levels of NGAL were in most SCD patients, which did not correlate with increasing albuminuria. Our findings suggest that KIM-1 and nephrin maybe reliable biomarkers for identifying early SCN.
As SCD is characterized by a chronic state of oxidative stress, we evaluated ROS in peripheral cells and renal tissue. We found that non-sickle mice demonstrated low oxidant stress in peripheral RBCs and white blood cells. Although treatment with atorvastatin did not significantly decrease oxidant stress in RBCs, there was a significant decrease in oxidant stress in macrophages, with a trend towards decreased ROS in neutrophils of sickle mice. Increased white blood cell count is an independent predictor of adverse outcomes in SCD (Miller et al, 2000) . In addition, macrophages may have a role in the activation of the endothelium as well as the perpetuation of pro-inflammatory markers (Vinchi et al, 2016) . Both endothelial and monocytic cells in culture respond to oxidized cysteine-cystine with proinflammatory signalling and increased cell adhesion. The major thiol/disulfide redox couple in human plasma is cysteine and its disulfide form, cystine. In our study, we found significant reduction of this thiol pair in renal tissues between treated and non-treated sickle mice. Key redox events of inflammatory processes are controlled by the redox state of CYS/CYSS at the extracellular surface of endothelial cell (Go & Jones, 2011) . In addition to our observations of decreased oxidant stress in the kidney, both Cybb and Nox4 responded to atorvastatin treatment with decreased expression. Nox4 and Cybb have been implicated as contributing to oxidant stress in the kidney and in the vasculature, respectively. Indeed, a recent study of diabetic nephropathy in mice found decreased expression of Nox4 with statin treatment (Fujii et al, 2007) . In addition, Cybb mRNA expression in sickle cell mice has been found to be significantly decreased in the kidney following treatment with an endothelin type A (ET A ) receptor blocker (Heimlich et al, 2016) .
Previous studies have demonstrated elevated levels of serum, urine and renal EDN1 (also termed ET1) levels in sickle mice when compared to control non-sickle phenotype (Sabaa et al, 2008) . EDN1 is a potent vasoconstrictor and has been shown to exacerbate hypoxia/reoxygenation injury in sickle cell mice (Sabaa et al, 2008) . EDN1 is synthesized in the endothelium of the renal vasculature, mesangial cells, peritubular capillaries, in the epithelium of the proximal tubule, thick ascending limb and the collecting duct, and in the inner medullary-collecting duct (Prabhakar, 2013) . These areas of EDN1 synthesis are quite susceptible to hypoxic injury, which in SCD frequently occurs due to recurrent episodes of vaso-occlusion. Although EDN1 (ETI) may bind to both ET A and ET B receptors, it has increased affinity to the ET A receptor binding in the renal vasculature (Sabaa et al, 2008) . Recent work by Kasztan et al (2017) demonstrated reduced albuminuria, decreased oxidative stress and inflammatory markers in mice treated with an ET A antagonist. We found that mRNA expression of Edn1 significantly decreased in kidney tissue following treatment with atorvastatin. In addition to changes seen with EDN1 expression, plasma sVCAM-1 decreased with atorvastatin treatment, further supporting the role of atorvastatin in stabilizing the renal endothelium in SCD.
Our results demonstrate that atorvastatin may offer a potential therapeutic option for the treatment of SCN. The mechanism of improvement of renal pathologies in sickle mice may be related to the ability of atorvastatin to improve endothelial function and decrease ROS. Further studies exploring whether the addition of ACEI, ARB or hydroxyurea would provide additive or synergistic benefit in the treatment of SCN are a future target.
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